Memo
“Dr. Rose said, “I very much look forward to being an integral part of Mesoblast’s leadership management team at such a pivotal moment in the Company’s history. Having seen first-hand at Board level the tremendous potential of our technology to achieve remarkable clinical outcomes in the most refractory of inflammatory conditions, I feel privileged to be able to contribute in a more comprehensive way to help steer our therapies through the final but crucial stages of regulatory approval and commercialization.”.
I like reading this from time to time .
MSB 2022 - The road to commercialisation, page-1359
-
- There are more pages in this discussion • 170 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |